{
    "clinical_study": {
        "@rank": "120823", 
        "arm_group": [
            {
                "arm_group_label": "Treatment Group 1", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Treatment Group 2", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Treatment Group 3", 
                "arm_group_type": "Experimental"
            }, 
            {
                "arm_group_label": "Treatment Group 4", 
                "arm_group_type": "Active Comparator"
            }, 
            {
                "arm_group_label": "Treatment Group 5", 
                "arm_group_type": "Placebo Comparator"
            }
        ], 
        "brief_summary": {
            "textblock": "The primary objective of the study was to examine the efficacy and safety of\n      S-555739/cetirizine HCl compared with the individual components and placebo."
        }, 
        "brief_title": "Combination Study Of S-555739/Cetirizine HCl In Adult Patients With Seasonal Allergic Rhinitis", 
        "completion_date": {
            "#text": "May 2013", 
            "@type": "Actual"
        }, 
        "condition": "Seasonal Allergic Rhinitis", 
        "condition_browse": {
            "mesh_term": [
                "Rhinitis, Allergic, Seasonal", 
                "Rhinitis"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  History and diagnosis of seasonal allergic rhinitis by skin prick test\n\n          -  Have nasal symptom scores as defined by the study protocol\n\n          -  Able to comply with study procedures\n\n        Exclusion Criteria:\n\n          -  Any nasal disease or abnormality, active respiratory tract infections within the past\n             2 weeks, or recent nasal surgery or sinus surgery at Screening\n\n          -  Use of any prohibited concomitant drugs or therapies"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "64 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "779", 
            "@type": "Actual"
        }, 
        "firstreceived_date": "July 17, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01651871", 
            "org_study_id": "1210D1526"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Treatment Group 1", 
                    "Treatment Group 3"
                ], 
                "intervention_name": "S-555739 Dose 1", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Treatment Group 2", 
                "intervention_name": "S-555739 Dose 2", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Treatment Group 4", 
                    "Treatment Group 1", 
                    "Treatment Group 2"
                ], 
                "intervention_name": "Cetirizine HCl Dose 1", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Treatment Group 4", 
                    "Treatment Group 5", 
                    "Treatment Group 2"
                ], 
                "intervention_name": "S-555739 placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Treatment Group 3", 
                    "Treatment Group 5"
                ], 
                "intervention_name": "Cetirizine HCl placebo", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Cetirizine", 
                "Anti-Allergic Agents"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": [
            "Agents, anti allergic", 
            "Nasal congestion", 
            "Sneezing", 
            "Nasal discharge", 
            "D prostanoid (DP) receptor antagonist"
        ], 
        "lastchanged_date": "May 30, 2013", 
        "number_of_arms": "5", 
        "official_title": "A Phase 2, Multicenter, Parallel-Group, Randomized, Double-Blind, Placebo- And Active Comparator-Controlled, Combination Study Of S-555739 And Cetirizine HCl In Adult Patients With Seasonal Allergic Rhinitis", 
        "overall_official": {
            "affiliation": "Shionogi", 
            "last_name": "Shionogi Clinical Trials Administrator Clinical Support Help Line", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "November 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": [
            {
                "measure": "Change in average morning/evening (AM/PM) reflective Total Nasal Symptom Score (rTNSS)", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline through the 2-week treatment period (Day 2 through Day 15)"
            }, 
            {
                "measure": "Incidence of adverse events (AEs)", 
                "safety_issue": "Yes", 
                "time_frame": "From Screening period to Week 6 (Follow-up)"
            }
        ], 
        "removed_countries": {
            "country": "United States"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01651871"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Change in average AM/PM instantaneous Total Nasal Symptom Score (iTNSS)", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline through the 2-week treatment period (Day 2 through Day 15)"
            }, 
            {
                "measure": "Change in average AM/PM Total Ocular Symptom Score", 
                "safety_issue": "No", 
                "time_frame": "Change from baseline through the 2-week treatment period (Day 2 through Day 15)"
            }, 
            {
                "measure": "Assessment of Quality of Life", 
                "safety_issue": "No", 
                "time_frame": "Change from Week 3 to Week 5"
            }, 
            {
                "measure": "Assessment of vital signs", 
                "safety_issue": "Yes", 
                "time_frame": "At Week 1 (Screening), Week 2, Week 3, Week 4, and Week 5"
            }, 
            {
                "measure": "Assessment of clinical laboratory parameters", 
                "safety_issue": "Yes", 
                "time_frame": "At Week 1 (Screening), Week 4, Week 5, and Week 6 (Follow-up)"
            }, 
            {
                "measure": "Assessment of electrocardiogram (ECG) findings", 
                "safety_issue": "Yes", 
                "time_frame": "At Week 1 (Screening) and Week 5"
            }
        ], 
        "source": "Shionogi Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Shionogi", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "July 2012", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor), Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2013"
    }
}